You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
BridgeBio reported $353.2 million in third-quarter 2026 revenue, including $253.2 million of U.S. Atrube net product revenue, up approximately 134% year-over-year. BBP418, infagratinib, and incalorate have PDUFA dates of November 27th, February 4, 2027, and May 8, 2027.
BridgeBio Pharma reported a nine-month net loss of $382.9 million versus $538.3 million in 2025, while net product revenue increased $440.0 million. It raised $933.9 million through preferred stock, with $500.0 million still available under its ATM offering.
BridgeBio Pharma, Inc. reported third-quarter total revenues, net of $353.2 million, including $253.2 million of U.S. Attruby net product revenue. PDUFA dates are November 27, 2026 for BBP-418, February 4, 2027 for oral infigratinib, and May 8, 2027 for encaleret.
BridgeBio Pharma, Inc. announced FDA acceptance of oral infigratinib for children with achondroplasia with Priority Review, assigning a PDUFA target action date of February 4, 2027.
